Osteoporosis International最新文献

{"title":"The effect of denosumab on minimum 3-years BMD changes in patients with osteoporotic hip fractures: a propensity score matching analysis.","authors":"Chul-Ho Kim, Keunho Kim, Ji Wan Kim","doi":"10.1007/s00198-024-07314-y","DOIUrl":"10.1007/s00198-024-07314-y","url":null,"abstract":"<p><p>Denosumab significantly increased lumbar spine and total hip bone mineral density in patients with hip fractures, with comparable efficacy to that in other than hip fracture patients. Its effect was more pronounced in medication-naïve patients, suggesting its efficacy regardless of hip fracture status.</p><p><strong>Purpose: </strong>Denosumab, a potent antiresorptive agent, has been recognised to increase bone mineral density (BMD) and reduce fracture risk in vertebrae and hips. Despite its widespread use, no sequential follow-up studies have investigated its effects on BMD in patients with hip fractures. This study aimed to analyse the effect of denosumab on BMD gain in patients with hip fractures and investigate the incidence of subsequent hip fractures.</p><p><strong>Methods: </strong>This retrospective study analysed 371 patients treated with denosumab for at least 3 years, including 122 patients with hip fractures. 1:1 propensity score matching was used to compare BMD changes in the lumbar spine, total hip, and femoral neck, as well as additional hip fracture incidence between the hip fracture and the other than hip fracture group. Ultimately, 122 patients in each group were compared. Subgroup analysis compared osteoporosis medication-naïve patients with those with prior medication use.</p><p><strong>Results: </strong>The hip fracture and other than hip fracture group exhibited significant annual increases in lumbar spine and total hip BMD, with no significant differences between them after matching. The femoral neck BMD increased significantly only in the first year. The incidence of additional hip fractures did not differ significantly between the groups. Moreover, the effect of denosumab on BMD increase was more pronounced in patients without a previous medication history for anti-osteoporosis treatment than in those with such a history.</p><p><strong>Conclusion: </strong>Denosumab significantly increased lumbar spine and total hip BMD in patients with hip fractures, with comparable efficacy to that in other than hip fracture patients. Its effect was more pronounced in medication-naïve patients, suggesting its efficacy regardless of hip fracture status.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"265-274"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral femoral neck fractures in pregnancy suggestive of transient osteoporosis of the hip in a patient with hyperparathyroidism: a case report.","authors":"Ryan J Blake, Vincent K Melemai, Brody M Fitzpatrick, David F Hubbard, Matthew J Dietz, Colleen M Watkins","doi":"10.1007/s00198-024-07346-4","DOIUrl":"10.1007/s00198-024-07346-4","url":null,"abstract":"<p><p>Atraumatic bilateral femoral neck fractures are rare, especially in younger patients and those without significant comorbidities. However, pregnant individuals appear to be at increased risk due to normal physiological changes in calcium balance, leading to transient osteoporosis of the hip. In these individuals, calcium and bone mineral density are generally decreased, reflecting the calcium demands of the developing fetus. Therefore, peripartum non-osteoporotic bilateral femoral neck fractures sustained remain a rare presentation. A 31-year-old patient presented with worsening hip pain; imaging studies revealed bilateral femoral neck fractures. A complicated birth requiring specialized maneuvers 11 months prior resulted in moderate hip pain, and a single step down from the bottom rung of a ladder approximately 7 months after the delivery initiated acute exacerbation of the hip pain. Orthopedic evaluation determined that the patient would benefit most from the surgical fixation of both femoral necks with an arthroplasty on the right and a dynamic hip screw on the left. Rheumatologic evaluation of the patient revealed no relevant risk factors for osteoporosis other than suboxone use, tobacco use, and low levels of vitamin D. A DXA scan was unremarkable, and interestingly, the only notable laboratory findings were markedly increased parathyroid hormone levels with a slight increase in calcium. Pregnant patients with high serum levels of parathyroid hormone might be at risk for atraumatic hip fractures regardless of serum calcium levels, particularly when maneuvers that put stress on the femoral neck are employed. This case demonstrates the importance of increased clinical suspicion of hip fractures and evaluation for hyperparathyroidism in a patient presenting with atypical hip pain immediately following labor.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"333-337"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author response to: Comment from Dongdong Cao, et al. on: Rapid reduction in fracture risk after the discontinuation of long-term oral glucocorticoid therapy: a retrospective cohort study using a nationwide health insurance claims database in Japan.","authors":"Masayuki Iki, Kenji Fujimori, Nobukazu Okimoto, Shinichi Nakatoh, Junko Tamaki, Shigeyuki Ishii, Hironori Imano, Sumito Ogawa","doi":"10.1007/s00198-025-07383-7","DOIUrl":"10.1007/s00198-025-07383-7","url":null,"abstract":"","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"363-364"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardization of the nomenclature of bone status indices: a milestone in diagnostic consistency and clarity.","authors":"Etienne Cavalier, Richard Pikner, Samuel D Vasikaran, Harjit Pal Bhattoa, Konstantinos Makris, Eugene V McCloskey, Nicholas C Harvey, Niklas Rye Jørgensen, Giovanni Lombardi","doi":"10.1007/s00198-024-07339-3","DOIUrl":"10.1007/s00198-024-07339-3","url":null,"abstract":"","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"161-162"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale for osteoporosis screening in men.","authors":"Radhika R Narla, Robert A Adler","doi":"10.1007/s00198-024-07337-5","DOIUrl":"10.1007/s00198-024-07337-5","url":null,"abstract":"<p><p>The US Preventive Services Task Force has not recommended osteoporosis screening in men. Department of Veterans Affairs clinicians reviewed the literature on male osteoporosis screening and treatment. They concluded that targeted screening identifies men at risk and osteoporosis drugs reduce fracture risk similarly in men and women.</p><p><strong>Purpose/introduction: </strong>The US Preventive Services Task Force (USPSTF) has found insufficient evidence for recommending for or against osteoporosis screening in men. Department of Veterans Affairs osteoporosis experts reviewed the literature on osteoporosis screening and treatment in men.</p><p><strong>Methods: </strong>Although not done systematically, the literature was reviewed by a panel of 20 Department of Veterans Affairs clinicians with extensive experience with osteoporosis in men. Virtual meetings and multiple email communications resulted in a consensus.</p><p><strong>Results: </strong>Screening, particularly targeted screening in men, has been found to identify men at risk for fracture. Prior studies have shown osteoporosis drugs have similar effects in men and women. A recent large observational trial demonstrated that hip fracture risk is similarly reduced for both sexes by current medications.</p><p><strong>Conclusion: </strong>The consensus of the panel was that targeted screening of men for osteoporosis would lead to greater use of osteoporosis medication, lowering fracture risk.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"163-166"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proactive strategies for fracture risk in androgen deprivation therapy: a call for multidisciplinary collaboration.","authors":"Muhammad Hunain Raza, Muhammad Eeman Bhutta, Muhammad Hammad Siddique","doi":"10.1007/s00198-024-07330-y","DOIUrl":"10.1007/s00198-024-07330-y","url":null,"abstract":"","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"369-370"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bisphosphonate drug holidays in osteoporosis according to fracture risk profile.","authors":"Asunción Salmoral, P Peris, C López Medina, H Flórez, M Barceló, M Pascual Pastor, I Ros, D Grados, P Aguado, S García, L López, L Gifre, D Cerdá, F J Aguilar, B Panero, E Costa, E Casado, B Hernández, A Martínez Ferrer, J Graña, I Gómez, N Guañabens","doi":"10.1007/s00198-024-07309-9","DOIUrl":"10.1007/s00198-024-07309-9","url":null,"abstract":"<p><p>We analyzed the incidence of fractures and changes in bone mineral density and bone turnover markers in 264 patients who discontinued bisphosphonates. Fractures were recorded in 12.3%. Half were clinical vertebral fractures. We identified patients with a high-risk profile who should not discontinue treatment.</p><p><strong>Objective: </strong>The optimal length of bisphosphonate discontinuation is unknown, as is the type of patient who could benefit from this approach. The objectives of the study were to analyze, in clinical practice, the incidence of fractures and associated risk factors, changes in bone mineral density (BMD) and bone turnover markers (BTMs) after discontinuation of bisphosphonates.</p><p><strong>Methods: </strong>This observational retrospective study included 264 patients from 14 Spanish rheumatology departments. Postmenopausal women or men with osteoporosis received alendronate or risedronate for ≥ 5 years or zoledronate for ≥ 3 years and had discontinued treatment for ≥ 1 year or ≥ 2 years, respectively. Spinal X-rays were obtained before discontinuation and in suspected clinical vertebral fracture during follow-up. BMD and BTMs were determined before discontinuation and at different time points.</p><p><strong>Results: </strong>The mean discontinuation time was 2.7 (± 6.7) years. Thirty-two patients (12.3%) had 36 fractures, mainly clinical vertebral fractures. The main risk factor for fracture was a high-risk profile (femoral neck T-score ≤ -2.5 and/or a history of fracture and/or multiple fractures [≥ 5 years]) before discontinuation. At 12 months, 10.41% of patients with high-risk profile experienced a fracture, being 0.8% and 1.08% in moderate- and low-risk patients, respectively. Significant BMD loss at the femoral neck and total hip was detected, with duration of discontinuation being the key factor. PINP was the marker with the greatest changes.</p><p><strong>Conclusions: </strong>We identified a profile of patients with osteoporosis who should not discontinue bisphosphonates, owing to the possibility of fractures, especially vertebral, which are already evident the first year after discontinuation.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"245-254"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142771151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteoporosis testing and treatment remain low in both Traditional Medicare and Medicare Advantage.","authors":"Tej D Azad, Rachel J Wu, Kelly E Anderson, Michael Darden, Amit Jain","doi":"10.1007/s00198-024-07318-8","DOIUrl":"10.1007/s00198-024-07318-8","url":null,"abstract":"<p><p>Little is known regarding osteoporosis management between Traditional Medicare (TM) and Medicare Advantage (MA). MA beneficiaries had higher rates of osteoporosis testing and higher rates of osteoporosis drug treatment initiation rates. Following an osteoporotic fragility fracture, MA beneficiaries were more likely to be prescribed osteoporosis treatment. While osteoporosis testing and treatment initiation rates are low in both TM and MA, rates tended to be higher in MA.</p><p><strong>Purpose: </strong>Osteoporosis represents a substantial clinical challenge in the United States, particularly for older women, and requires effective care coordination. Medicare Advantage (MA) plans have financial incentives in the form of star ratings to improve osteoporosis testing and treatment. The objective of this study was to compare osteoporosis management practices between Traditional Medicare (TM) beneficiaries and MA female enrollees.</p><p><strong>Methods: </strong>We conducted a cross-sectional study using a nationally representative 20% sample of 2017-2019 TM claims and MA encounter records. We identified 2,994,203 female TM beneficiaries and 1,924,132 MA enrollees. The exposure was enrollment in MA. The primary outcomes were the rates of guideline-recommended bone mineral density (BMD) testing and osteoporosis drug initiation following a new osteoporosis diagnosis and after a new osteoporotic fragility fracture.</p><p><strong>Results: </strong>MA beneficiaries had higher unadjusted (22.0% vs. 19.8% in TM; P < 0.001) and adjusted rates (0.8 percentage points [p.p.] higher; P < 0.001) of BMD testing. Osteoporosis drug treatment initiation rates were higher in the MA cohort, both unadjusted (24.9% vs. 20.3% in TM; P < 0.001) and adjusted (4.0 p.p. higher; P < 0.001). Following an osteoporotic fragility fracture, MA beneficiaries were more likely to be prescribed pharmacologic treatment (28.7% vs. 21.1% in TM; P < 0.001), with an adjusted increase of 5.9 p.p (P < 0.001).</p><p><strong>Conclusion: </strong>Overall osteoporosis testing and treatment initiation rates in both TM and MA enrollees were low, with improved rates in MA compared to TM.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"275-281"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence insights into osteoporosis: comment.","authors":"Hinpetch Daungsupawong, Viroj Wiwanitkit","doi":"10.1007/s00198-024-07102-8","DOIUrl":"10.1007/s00198-024-07102-8","url":null,"abstract":"","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"351"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Response to: Comment from Zahra Ali Haque, et al. on: Rapid reduction in fracture risk after the discontinuation of long-term oral glucocorticoid therapy: a retrospective cohort study using a nationwide health insurance claims database in Japan.","authors":"Masayuki Iki, Kenji Fujimori, Nobukazu Okimoto, Shinichi Nakatoh, Junko Tamaki, Shigeyuki Ishii, Hironori Imano, Sumito Ogawa","doi":"10.1007/s00198-024-07332-w","DOIUrl":"10.1007/s00198-024-07332-w","url":null,"abstract":"","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":"367-368"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}